bFGF peptide combined with the pVAX-8CpG plasmid as adjuvant is a novel anticancer vaccine inducing effective immune responses against Lewis lung carcinoma

Molecular Medicine Reports

Volumn 5, Issue 3, 2012, Pages 625-630

  Li, Meng ^a   Shi, Hua Shan ^a   Zhang, Hai Long ^a   Luo, Zi Chao ^b   Wan, Yang ^a   Lu, Lian ^a   Luo, Shun Tao ^a   Yang, Li ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Alum; pVAX nCpG; Truncated basic fibroblast growth factor; Tumor angiogenesis

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; PLASMID DNA; PVAX 8 CPG; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; LEWIS CARCINOMA; MOUSE; NONHUMAN; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, NEUTRALIZING; CANCER VACCINES; CARCINOMA, LEWIS LUNG; FEMALE; FIBROBLAST GROWTH FACTOR 2; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PLASMIDS; RECOMBINANT PROTEINS;

MUS;

EID: 84863042899     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.725     Document Type: Article

References (40)

1. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
2. Makrilia N, Lappa T, Xyla V, Nikolaidis I and Syrigos K: The role of angiogenesis in solid tumors: an overview. Eur J Intern Med 20: 663-671, 2009.
3. Han H, Silverman JF, Santucci TS, et al: Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol 8: 72-79, 2001. (Pubitemid 32126827)
4. Sridhar SS and Shepherd FA: Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 42: S81-S91, 2003. (Pubitemid 37378191)
5. Liotta LA, Steeg PS and Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64: 327-336, 1991. (Pubitemid 121001258)
6. Bikfalvi A, Javerzat S, Perollet C and Savona C: Angiogenesis and cancer. Bull Cancer 84: 885-890, 1997. (Pubitemid 27434218)
7. Bouck N, Stellmach V and Hsu SC: How tumors become angiogenic. Adv Cancer Res 69: 135-174, 1996. (Pubitemid 26274885)
8. Yang LP, Cheng P, Peng XC, et al: Anti-tumor effect of adenovirus-mediated gene transfer of pigment epithelium-derived factor on mouse B16-F10 melanoma. J Exp Clin Cancer Res 28: 75, 2009.
9. Beenken A and Mohammadi M: The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8: 235-253, 2009.
10. Plum SM, Holaday JW, Ruiz A, Madsen JW, Fogler WE and Fortier AH: Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. Vaccine 19: 1294-1303, 2000. (Pubitemid 32008298)
11. Neufeld G, Mitchell R, Ponte P and Gospodarowicz D: Expression of human basic fibroblast growth factor cDNA in baby hamster kidney-derived cells results in autonomous cell growth. J Cell Biol 106: 1385-1394, 1988.
12. Rogelj S, Weinberg RA, Fanning P and Klagsbrun M: Basic fibroblast growth factor fused to a signal peptide transforms cells. Nature 331: 173-175, 1988. (Pubitemid 18042150)
13. Sasada R, Kurokawa T, Iwane M and Igarashi K: Transformation of mouse BALB/c 3T3 cells with human basic fibroblast growth factor cDNA. Mol Cell Biol 8: 588-594, 1988. (Pubitemid 18044875)
14. Miyake H, Hara I, Yoshimura K, et al: Introduction of basic fibroblast growth factor gene into mouse renal cell carcinoma cell line enhances its metastatic potential. Cancer Res 56: 2440-2445, 1996. (Pubitemid 26154096)
15. Garlapati S, Facci M, Polewicz M, et al: Strategies to link innate and adaptive immunity when designing vaccine adjuvants. Vet Immunol Immunopathol 128: 184-191, 2009.
16. Liu Y, Sun L, Huan Y, Zhao H and Deng J: Application of bFGF and BDNF to improve angiogenesis and cardiac function. J Surg Res 136: 85-91, 2006. (Pubitemid 44634553)
17. Zhang HL, Yuan C, Zhang DM, et al: A novel combined conjugate vaccine: enhanced immunogenicity of bFGF with CRM197 as a carrier protein. Mol Med Rep 4: 857-863, 2011.
18. Ballas ZK, Rasmussen WL and Krieg AM: Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157: 1840-1845, 1996. (Pubitemid 126449654)
19. Zhang XP, Yang L, Shi HS, et al: An N-, C-terminally truncated basic fibroblast growth factor and LPD (liposome-polycation-DNA) complexes elicits a protective immune response against murine colon carcinoma. Cancer Biol Ther 10: 276-281, 2010.
20. Ni Y, Ma K, Ni J, Zheng X, Wang Y and Xiong S: A rapid and simple approach to preparation of monoclonal antibody based on DNA immunization. Cell Mol Immunol 1: 295-299, 2004.
21. Zhang HY, Sun SH, Guo YJ, et al: Immune response in mice inoculated with plasmid DNAs containing multiple-epitopes of foot-and-mouth disease virus. Vaccine 21: 4704-4707, 2003.
22. Bendigs S, Salzer U, Lipford GB, Wagner H and Heeg K: CpG-oligodeoxynucleotides co-stimulate primary T cells in the absence of antigen-presenting cells. Eur J Immunol 29: 1209-1218, 1999. (Pubitemid 29164167)
23. Hartmann G, Weiner GJ and Krieg AM: CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci USA 96: 9305-9310, 1999. (Pubitemid 29374750)
24. Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Review Immunol 20: 709-760, 2002.
25. Krieg AM and Davis HL: Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther 3: 15-24, 2001. (Pubitemid 32177965)
26. Kovacs-Nolan J, Latimer L, Landi A, et al: The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice. Vaccine 27: 2055-2064, 2009.
27. Lindblad EB: Aluminium compounds for use in vaccines. Immunol Cell Biol 82: 497-505, 2004.
28. HogenEsch H: Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 20: S34-S39, 2002.
29. Preparation of anionic poly (epsilon-caprolactone)-poly (ethylene glycol)-poly (epsilon-caprolactone) copolymeric nanoparticles as basic protein antigen carrier. Growth Factors 25: 202-208, 2007.
30. Chen X, Wang X, Wang Y, et al: Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J Control Release 145: 17-25, 2010.
31. Luo Z, Peng X, Shi H, Gong C, Qian Z and Yang L: Comparison of the protective effects of truncated bFGF and native bFGF against murine lung carcinoma. Int J Mol Med 28: 3-8, 2011.
32. Weidner N, Semple JP, Welch WR and Folkman J: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
33. Folkman J, Merler E, Abernathy C and Williams G: Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133: 275-288, 1971.
34. Hori A, Sasada R, Matsutani E, et al: Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 51: 6180-6184, 1991.
35. Inoue K, Perrotte P, Wood CG, Slaton JW, Sweeney P and Dinney CP: Gene therapy of human bladder cancer with adenovirus-mediated antisense basic fibroblast growth factor. Clin Cancer Res 6: 4422-4431, 2000.
36. Davidson JM, Klagsbrun M, Hill KE, et al: Accelerated wound repair, cell proliferation, and collagen accumulation are produced by a cartilage-derived growth factor. J Cell Biol 100: 1219-1227, 1985. (Pubitemid 15093475)
37. Hayek A, Culler FL, Beattie GM, Lopez AD, Cuevas P and Baird A: An in vivo model for study of the angiogenic effects of basic fibroblast growth factor. Biochem Biophys Res Commun 147: 876-880, 1987. (Pubitemid 18007026)
38. Ioannou XP, Gomis SM, Karvonen B, Hecker R, Babiuk LA and van Drunen Littel-van den Hurk S: CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Vaccine 21: 127-137, 2002.
39. Weeratna RD, McCluskie MJ, Xu Y and Davis HL: CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 18: 1755-1762, 2000. (Pubitemid 30122837)
40. Kindrachuk J, Jenssen H, Elliott M, et al: A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. Vaccine 27: 4662-4671, 2009.